BRAF and melanoma: Subsequent results from clinical studies such as DREAMseq 36 and SECOMBIT 37, which compared immunotherapy first or targeted therapy first in patients with advanced melanoma and BRAF V600 mutations, were not available at the time our study was conducted, although ultimately supported the use of nivolumab plus ipilimumab as frontline therapy for this patient population.